BCL2L1 and glioblastoma: Studies have shown that this combination effectively eliminates senescent fibroblasts, prolongs survival rates, and delays the onset of age-related diseases in mice.[61] A proven senolytic drug, the BCL-XL/BCL-2 inhibitor ABT-263 (navitoclax), induces apoptosis in senescent prostate cancer cells, thereby inhibiting proliferative recovery and tumor cell development.[18] According to a previous study, radiation therapy induces senescence in non-tumor brain cells to promote glioblastoma recurrence, implying that senolytic therapy can inhibit the growth and invasiveness of recurrent glioblastoma.